Men's health supplements: the rules and how to build one
In short
- A men's health supplement with a health claim is a medicine, usually listed. Its claims sit in Part 10 (the reproductive system) of the Permissible Indications Determination, and the bladder and urinary claims in Part 13.
- The prostate claims must not imply or refer to serious genitourinary conditions such as benign prostatic hypertrophy, erectile dysfunction or hormone therapy.
- The sperm and semen claims, and the testosterone claims, can only rest on scientific evidence. The sperm claims must not imply or refer to infertility.
- Saw palmetto, fenugreek and lycopene are permitted actives with no specific requirements. Zinc is limited to 50 mg a day, with a warning above 25 mg.
- From our records: ATP Science's TGA-listed capsule built on Testofen®, and a prostate formula among the nine products for an established natural health company.
Why a men's health supplement is a medicine
A capsule, tablet or powder presented for a therapeutic use, such as supporting prostate health or healthy testosterone levels, is a medicine, and most are listed medicines (AUST L). Every ingredient comes from the Permissible Ingredients Determination, every claim from the Permissible Indications Determination, and the sponsor holds the evidence for each before the product is sold (TGA approval). A product presented for sport or recovery and supplied as a capsule or tablet is usually a medicine too (sports supplements).
The men's health claims a listed medicine can make
Under section 6 of the Therapeutic Goods (Permissible Indications) Determination (No. 1) 2025, a claim can only be used if it is supported by the type of evidence its item names, and its requirements must be met (permitted indications). Part 10 covers the reproductive system for men and women together. The claims most men's products use:
| Claim (as worded in the Determination) | Where | Evidence | Requirements |
|---|---|---|---|
| Maintain/support prostate health | Part 10, item 48 | Scientific or traditional | Must not imply or refer to serious genitourinary conditions like Benign Prostatic Hypertrophy, erectile dysfunction or hormone therapy |
| Help maintain/support healthy prostate function | Part 10, item 22 | Scientific or traditional | As above |
| Helps enhance/promote prostate health | Part 10, item 27 | Scientific or traditional | As above |
| Maintain/support testosterone level | Part 10, item 54 | Scientific only | None |
| Helps maintain/support testosterone formation/synthesis | Part 10, item 30 | Scientific only | None |
| Maintain/support healthy reproductive hormones | Part 10, item 44 | Scientific or traditional | Must not imply or refer to hormone imbalances |
| Maintain/support healthy libido | Part 10, item 43 | Scientific or traditional | None |
| Maintain/support healthy sexual function | Part 10, item 45 | Scientific or traditional | None |
| Maintain/support sperm health | Part 10, item 51 | Scientific only | Must not imply or refer to infertility |
| Maintain/support sperm motility | Part 10, item 52 | Scientific only | As above |
| Maintain/support sperm production | Part 10, item 53 | Scientific only | As above |
| Male tonic | Part 10, item 59 | Traditional only | None |
Part 10 has no claim about male infertility or erectile dysfunction, and the prostate claims rule out benign prostatic hypertrophy by name. Where the evidence is traditional, the claim carries a traditional context qualifier on the label. Qualifiers for a population, such as a sex or an age group, come from the TGA's code tables, under section 5, as our women's health guide shows for "In females".
The urinary claims
Prostate products often sit beside bladder and urinary claims, which are in Part 13. Those that carry no requirement include "Maintain/support bladder health" (item 14), "Maintain/support healthy bladder function" (item 15), "Maintain/support urinary tract health" (item 21) and "Aid/assist flushing of the urinary tract" (item 1). "Relieve urinary frequency" (item 23) carries the label statement "If symptoms persist, talk to your health professional." The claims about urine output, kidney function and urinary tract function must not imply or refer to kidney disease, and the cystitis and overactive bladder claims must refer only to a medically diagnosed condition, with label statements of their own.
The same limits apply on the website, in social posts and in any ad, as on the label (TGA advertising).
Men's health ingredients
The Therapeutic Goods (Permissible Ingredients) Determination (No. 3) 2026, in force since 16 October 2026, sets each ingredient's purposes and limits (permissible ingredients):
- Serenoa repens (saw palmetto, item 4511): permitted as an active or homoeopathic ingredient, not as an excipient, with no specific requirements.
- Trigonella foenum-graecum (fenugreek, item 5032): permitted as an active, with no specific requirements. Testofen® is a clinically studied fenugreek extract (branded ingredients).
- Prunus africana (item 4194): amygdalin and hydrocyanic acid are mandatory components, and the medicine must contain no more than 10 mg/kg of each.
- Lycopene (item 3102): permitted as an active, with no specific requirements.
- Zinc, as zinc citrate (item 5265) or zinc gluconate (item 5269), for example: for internal use, no more than 50 mg of zinc in the maximum recommended daily dose. Between 25 mg and 50 mg, the label must carry "WARNING: May be dangerous if taken in large amounts or for a long period." or the version that names zinc.
In prostate supplement formulation, as in any men's formula, every other ingredient is checked against its own entry at the brief. An ingredient that isn't in the Determination needs an application to the TGA first (new ingredients).
From our records
- ATP Science's core range: a private-equity-backed Australian sports and wellness brand, turning over A$24 million a year by 2019 and exporting to New Zealand, the UK and the UAE. Several of its best-known formulas had room to improve on ingredient quality, dose and permitted indications, so we reformulated four TGA-listed capsules from scratch, one built on Testofen®, plus a food-pathway performance powder. Five products in production from late 2023, with reorders on three of them within a year.
- An established natural health company: across the relationship we developed and quoted nine products for the brand, spanning eye health, omega-3s, probiotics, liver, immune, prostate and more, and took three into production.
Questions
Frequently asked questions
Yes, on scientific evidence. "Maintain/support testosterone level" and "Helps maintain/support testosterone formation/synthesis" are in Part 10 of the Permissible Indications Determination.
No. The prostate claims require that the presentation not imply or refer to serious genitourinary conditions like benign prostatic hypertrophy, erectile dysfunction or hormone therapy.
It can claim to support sperm health, motility or production, on scientific evidence, but the presentation must not imply or refer to infertility.
Yes. Serenoa repens is a permissible active ingredient, with no specific requirements in its entry. It isn't permitted as an excipient.
No more than 50 mg of zinc in the maximum recommended daily dose for internal use. Above 25 mg, the label needs a warning that it may be dangerous if taken in large amounts or for a long period.
Keep reading
Keep reading
Reformulating a supplement: when a product has to change
Reformulating a TGA-listed supplement: which changes make a new listing, which update yours, the stability evidence, and reformulations from our records.
How long does it take to develop a supplement?
How long it takes to develop a supplement, from our records: 32 days from design to production order at the fastest, the stages, and what holds a launch up.
Exporting an Australian-made supplement: export-only listings and TGA certificates
Exporting a supplement made in Australia: export-only ARTG listings, the TGA's CPP and CLP certificates, 2026–27 fees, and what the importing country decides.
Extending a supplement range: your next product, and the one after
Supplement range extension in Australia: what each new product needs from the TGA, what carries over from your first, and how brands we work with grew.
Sources
General information, checked against these sources on 16 November 2026. It isn't advice on a particular product. Our work is from Take Friday Off's records.
- Therapeutic Goods (Permissible Indications) Determination (No. 1) 2025, sections 5 and 6 and Schedule 1, Parts 10 and 13, Federal Register of Legislation
- Therapeutic Goods (Permissible Ingredients) Determination (No. 3) 2026, section 6 and Schedule 1, items 3102, 4194, 4511, 5032, 5265 and 5269, Federal Register of Legislation
